DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer [0.03%]
DABCLA-13研究：Ta低级别尿路上皮复发性膀胱癌化学切除术联合术后膀胱内丝裂霉素C灌注五年随机对照试验随访结果报告
Søren Klingenberg,Maria S Lindgren,Jakob K Jakobsen et al.
Søren Klingenberg et al.
Background and objective: Transurethral resection of bladder tumors (TURBT) remains the standard treatment for non-muscle-invasive bladder cancer (NMIBC) but is associated with procedural risks and health care burden. Che...
Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective [0.03%]
尿路上皮膀胱癌的血液和尿液循环肿瘤DNA：现状与临床展望
Igor Duquesne,Isabelle Epelbaum,Doriane Prost et al.
Igor Duquesne et al.
Background and objective: Urothelial bladder cancer (UBC) carries significant mortality and treatment morbidity. Conventional diagnostic and monitoring methods, including cystoscopy and biopsy, are invasive and limited in...
Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14) [0.03%]
恩扎卢胺联合二甲双胍与单用恩扎卢胺治疗转移性去势抵抗性前列腺癌的随机Ⅱ期临床研究（SAKK 08/14）
S Gillessen,K Gobat,R Cathomas et al.
S Gillessen et al.
Background and objective: The aim of our study is to determine whether the addition of metformin to enzalutamide can improve the outcomes of men with metastatic castration-resistant prostate cancer (mCRPC). ...
Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway [0.03%]
前列腺癌诊断途径效益和危害评估关键绩效指标解析
Anwar R Padhani,Sigrid Carlsson,Ola Bratt et al.
Anwar R Padhani et al.
Traditional accuracy metrics no longer suffice for comparing diagnostic pathways for prostate cancer; new comparative performance metrics are needed that prioritize the overall benefit-to-harm ratio. Key performance metrics, such as biopsy ...
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer [0.03%]
IMU-935（一种新颖的RORγ/RORγt逆激动剂）单药治疗转移性去势抵抗性前列腺癌患者的1期开放标签剂量递增研究
Rafael Grochot,Christina Guo,Suzanne Carreira et al.
Rafael Grochot et al.
Background and objective: Retinoic acid receptor-related orphan receptor gamma (RORγ) is frequently overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and, together with retinoic acid-related orphan...
Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol [0.03%]
前列腺癌的靶向和局部与系统活检：TARGET临床试验方案
Michael Baboudjian,Federica Sordelli,Jean-Jacques Patard et al.
Michael Baboudjian et al.
Background and objective: Multiparametric magnetic resonance imaging (mpMRI) with targeted biopsies improves detection of clinically significant prostate cancer (csPC), commonly defined as Gleason grade group (GG) ≥2. Cu...
Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer [0.03%]
18F-FDG正电子发射断层显像/计算机体层成像对膀胱癌病理分型分期的诊断价值分析
Renee A G Lijnen,Joanneke B Ringia,Francesco Claps et al.
Renee A G Lijnen et al.
Background and objective: Up to 25% of bladder cancer cases harbour histological subtypes (HSs) distinct from conventional urothelial carcinoma (UC), often with more aggressive behaviour and variable treatment response. A...
Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary toxicity After Prostate RT: Insights from IRRADIaTE, the Italian Registry of RT-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.01.005 [0.03%]
意大利放射治疗相关障碍和泌尿系统治疗及评估 registry（IRRADIAte）的 real-world 数据：前列腺放疗后迟发性泌尿系统毒性的负担和管理
Riccardo Bertolo,Alessandro Antonelli
Riccardo Bertolo
Reply to: Letter to the Editor EUONCO-D-26-00110 Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary toxicity After Prostate RT: Insights from IRRADIaTE, the Italian Registry of RT-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In press. https://doi. [0.03%]
关于前列腺放射治疗后泌尿系统晚期毒性真实世界负担和管理的信件回应文章：来自意大利放射治疗相关疾病及泌尿治疗与评估登记处的见解
Riccardo Bertolo,Alessandro Antonelli
Riccardo Bertolo
A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity [0.03%]
基于长链非编码RNA的低级别Ta膀胱癌患者预后危险分类器模型的建立及临床意义研究
Tran Anh Thu Phung,Rachel Weng,Peter C Black et al.
Tran Anh Thu Phung et al.
Background and objective: Low-grade, stage Ta (TaLG) non-muscle-invasive bladder cancer (NMIBC) is generally nonaggressive; yet, some patients experience recurrence or progression. We previously identified long noncoding ...